Can I add that what I would actually hope & expect them to be doing would be something like an evidence-based meta-analysis of all the available data. I would hope that ongoing studies would release their data early to the MHRA and JCVI to make all the relevant information available as early as possible, so that data trends can be picked up.
So something very evidence-based and medical/ pharmacological looking at trends in terms of who is vulnerable to the most severe illness with covid and what the risks are.
I would not expect there to be very much variation between the UK & US for a lot of this other than issues around ethnicity & deprivation leading to vulnerability - there would be different profiles in different areas - and also different medical practice / availability of ICU beds would be relevant.
There is a cost/ benefit ratio for deciding on whether a medication is appropriate, but a lot of that work would already have been done by the MHRA.
I'd expect them to take into account factors like the beginning of term & the fact that rollout takes time.
I think cost is in the mix also.
I think it is surprising that we are choosing to do vaccination 12-15 so very differently from Europe & the US and I think it warrants more explanation actually. Why not make the offer to all CEV kids who were shielding, for example?
JVT has said it isn't about supply (and was saying several weeks ago that he expected a wider roll out to 12-15s to be forthcoming).